Role of pretrial systemic opioid requirements, intrathecal trial dose, and non-psychological factors as predictors of outcome for intrathecal pump therapy: one clinician's experience with lumbar postlaminectomy pain
- PMID: 21992206
- DOI: 10.1111/j.1525-1403.2011.00333.x
Role of pretrial systemic opioid requirements, intrathecal trial dose, and non-psychological factors as predictors of outcome for intrathecal pump therapy: one clinician's experience with lumbar postlaminectomy pain
Abstract
Objective: Non-psychological parameters may predict pump success.
Methods: Review was performed on 35 implants for gender, age, pretrial/trial dose, baseline visual analog scale (VAS), and pain location. One-year outcomes were % change VAS/intrathecal dose and medication change. Spearman coefficients correlated pretrial/trial dose, age, baseline VAS, and % change in VAS/intrathecal dose. Wilcoxon Rank-Sum tests correlated gender/pain location and % change in VAS/intrathecal dose. Pretrial/trial dose, baseline VAS, and medication change was tested using Wilcoxon Rank-Sums. Chi-square was used to correlate medication change with gender/pain location. A two-sample t-test compared age and medication change.
Results: Positive correlation between % change VAS and trial dose was noted. Greater age correlated with lower VAS and % dose change. Marginally significant difference in % dose change by pain location was present with higher doses for leg pain.
Conclusion: Trial dose, age, and partially pain location are good predictors of pain relief.
© 2011 International Neuromodulation Society.
Similar articles
-
Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain.Pain Physician. 2011 Jul-Aug;14(4):343-51. Pain Physician. 2011. PMID: 21785477 Review.
-
Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine.Spine J. 2002 Jul-Aug;2(4):274-8. doi: 10.1016/s1529-9430(02)00199-7. Spine J. 2002. PMID: 14589479
-
Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations.J Pain Symptom Manage. 2003 Jul;26(1):668-77. doi: 10.1016/s0885-3924(03)00144-1. J Pain Symptom Manage. 2003. PMID: 12850649 Clinical Trial.
-
Age-dependent intrathecal opioid escalation in chronic noncancer pain patients.Pain Med. 2011 Aug;12(8):1179-89. doi: 10.1111/j.1526-4637.2011.01188.x. Epub 2011 Aug 2. Pain Med. 2011. PMID: 21810164
-
Intrathecal opioids for intractable pain syndromes.Acta Neurochir Suppl. 2007;97(Pt 1):43-8. doi: 10.1007/978-3-211-33079-1_5. Acta Neurochir Suppl. 2007. PMID: 17691355 Review.
Cited by
-
Intrathecal therapy for chronic pain: current trends and future needs.Curr Pain Headache Rep. 2014 Jan;18(1):388. doi: 10.1007/s11916-013-0388-x. Curr Pain Headache Rep. 2014. PMID: 24338701 Review.
-
Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency.J Pain Res. 2014 Oct 3;7:571-7. doi: 10.2147/JPR.S46929. eCollection 2014. J Pain Res. 2014. PMID: 25336986 Free PMC article. Review.
-
Intrathecal Analgesia for Chronic Refractory Pain: Current and Future Prospects.Drugs. 2015 Nov;75(17):1957-80. doi: 10.1007/s40265-015-0471-1. Drugs. 2015. PMID: 26501979 Review.
-
Narrative review of intrathecal drug delivery (IDD): indications, devices and potential complications.Ann Transl Med. 2021 Jan;9(2):186. doi: 10.21037/atm-20-3814. Ann Transl Med. 2021. PMID: 33569488 Free PMC article. Review.
-
Intrathecal pain management: a team-based approach.J Pain Res. 2017 Nov 3;10:2565-2575. doi: 10.2147/JPR.S142147. eCollection 2017. J Pain Res. 2017. PMID: 29138593 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical